Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
Tevogen Bio (Nasdaq: TVGN) announced that its CIO & Head of Tevogen.AI, Mittul Mehta, participated as a featured speaker at Proskauer's AI discussion panel titled 'Attuned AI: Shaping AI to Empower Your Industry' on March 6, 2025, in New York City.
The panel, which included executives from Perplexity and Harvey, focused on AI's transformation of the finance, biotech, and legal sectors. Mehta discussed Tevogen.AI's approach to AI-driven biotech advancements, highlighting applications in precision medicine and operational efficiencies.
The event was moderated by Proskauer Partner Wai Choy, who praised Tevogen.AI's combination of proprietary datasets with generative AI models for biotech discovery and development.
Tevogen Bio (Nasdaq: TVGN) ha annunciato che il suo CIO e Responsabile di Tevogen.AI, Mittul Mehta, ha partecipato come relatore principale al panel di discussione sull'IA di Proskauer intitolato 'Attuned AI: Shaping AI to Empower Your Industry' il 6 marzo 2025, a New York City.
Il panel, che includeva dirigenti di Perplexity e Harvey, si è concentrato sulla trasformazione dell'IA nei settori della finanza, biotecnologia e legale. Mehta ha discusso l'approccio di Tevogen.AI ai progressi biotecnologici guidati dall'IA, evidenziando applicazioni nella medicina di precisione e nelle efficienze operative.
L'evento è stato moderato dal Partner di Proskauer Wai Choy, che ha elogiato la combinazione di dataset proprietari di Tevogen.AI con modelli di IA generativa per la scoperta e lo sviluppo biotecnologico.
Tevogen Bio (Nasdaq: TVGN) anunció que su CIO y Jefe de Tevogen.AI, Mittul Mehta, participó como ponente destacado en el panel de discusión sobre IA de Proskauer titulado 'Attuned AI: Shaping AI to Empower Your Industry' el 6 de marzo de 2025, en la ciudad de Nueva York.
El panel, que incluyó a ejecutivos de Perplexity y Harvey, se centró en la transformación de la IA en los sectores de finanzas, biotecnología y legal. Mehta discutió el enfoque de Tevogen.AI hacia los avances biotecnológicos impulsados por IA, destacando aplicaciones en medicina de precisión y eficiencias operativas.
El evento fue moderado por el socio de Proskauer Wai Choy, quien elogió la combinación de conjuntos de datos propios de Tevogen.AI con modelos de IA generativa para el descubrimiento y desarrollo biotecnológico.
Tevogen Bio (Nasdaq: TVGN)는 자사의 CIO이자 Tevogen.AI 책임자인 Mittul Mehta가 2025년 3월 6일 뉴욕에서 열린 Proskauer의 AI 토론 패널 'Attuned AI: Shaping AI to Empower Your Industry'에 주요 연사로 참여했다고 발표했습니다.
이 패널에는 Perplexity와 Harvey의 경영진이 포함되었으며, AI가 금융, 생명공학 및 법률 분야를 어떻게 변화시키고 있는지에 대해 논의했습니다. Mehta는 Tevogen.AI의 AI 기반 생명공학 발전 접근 방식을 논의하며 정밀 의학과 운영 효율성에서의 응용 사례를 강조했습니다.
이번 행사는 Proskauer의 파트너 Wai Choy가 진행했으며, Tevogen.AI의 독점 데이터셋과 생성적 AI 모델의 결합이 생명공학 발견 및 개발에 기여하는 점을 높이 평가했습니다.
Tevogen Bio (Nasdaq: TVGN) a annoncé que son CIO et Responsable de Tevogen.AI, Mittul Mehta, a participé en tant qu'intervenant principal au panel de discussion sur l'IA de Proskauer intitulé 'Attuned AI: Shaping AI to Empower Your Industry' le 6 mars 2025 à New York.
Le panel, qui comprenait des dirigeants de Perplexity et Harvey, s'est concentré sur la transformation de l'IA dans les secteurs de la finance, de la biotechnologie et du droit. Mehta a discuté de l'approche de Tevogen.AI en matière d'avancées biotechnologiques pilotées par l'IA, mettant en avant des applications en médecine de précision et en efficacité opérationnelle.
L'événement a été modéré par Wai Choy, partenaire chez Proskauer, qui a salué la combinaison des ensembles de données propriétaires de Tevogen.AI avec des modèles d'IA générative pour la découverte et le développement biotechnologique.
Tevogen Bio (Nasdaq: TVGN) gab bekannt, dass sein CIO und Leiter von Tevogen.AI, Mittul Mehta, am 6. März 2025 als Hauptredner an einem Diskussionspanel von Proskauer mit dem Titel 'Attuned AI: Shaping AI to Empower Your Industry' in New York City teilnahm.
Das Panel, an dem Führungskräfte von Perplexity und Harvey teilnahmen, konzentrierte sich auf die Transformation von KI in den Bereichen Finanzen, Biotechnologie und Recht. Mehta sprach über den Ansatz von Tevogen.AI zu KI-gesteuerten biotechnologischen Fortschritten und hob Anwendungen in der Präzisionsmedizin und betrieblichen Effizienz hervor.
Die Veranstaltung wurde von Proskauer-Partner Wai Choy moderiert, der die Kombination von proprietären Datensätzen von Tevogen.AI mit generativen KI-Modellen für die Entdeckung und Entwicklung in der Biotechnologie lobte.
- None.
- None.
WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, recently joined industry leaders at Proskauer’s AI discussion panel, "Attuned AI: Shaping AI to Empower Your Industry," held on March 6, 2025, in New York City.
Along with Mittul Mehta, the event featured Brooker Belcourt, General Manager of Finance from Perplexity, and Andrew Johnston, Strategic Business Development Manager from Harvey, to explore how AI is transforming the finance, biotech, and legal sectors. During the discussion, Mehta shared insights into Tevogen.AI’s pioneering approach to AI-driven advancements in biotech, highlighting practical applications, emerging trends, and strategies for leveraging AI to enhance precision medicine and operational efficiencies.
“As AI continues to reshape industries, it’s critical to tailor its potential to address the unique challenges and opportunities within each sector. At Tevogen.AI, we are committed to leveraging AI to accelerate innovation in precision medicine, making advanced therapies more accessible and affordable,” said Mehta.
The event, moderated by Proskauer Partner Wai Choy, a leader of the international law firm’s AI Practice, Technology, Media & Telecommunications Group and Life Sciences Group, featured an engaging conversation on the latest AI advancements and strategies, followed by a networking reception attended by industry professionals and thought leaders.
“It has been exciting to see Tevogen.AI combine its carefully curated proprietary datasets with its innovative application of generative AI models to derive valuable insights that are optimized for the specific needs of biotech discovery and development,” said Choy.
For more information, please visit Tevogen.AI
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/26077bb6-b115-49b2-93ce-5839e3f83af6
FAQ
What was discussed at Proskauer's AI panel featuring Tevogen Bio (TVGNW) in March 2025?
How is Tevogen Bio (TVGNW) implementing AI in its biotech operations?
Who were the key speakers at the Tevogen Bio (TVGNW) AI panel discussion?
What is Tevogen Bio's (TVGNW) stated goal for AI implementation in healthcare?
